Administration of a glypican‐3 peptide increases the infiltration and cytotoxicity of CD8+ T cells against testicular yolk sac tumor, associated with enhancing the intratumoral cGAS/STING signaling. Here, CGAS is linked to testicular yolk sac tumor.